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1. Introduction 
Mechanical ventilation (MV), while life saving, also carries significant risks and 
complications.  There is a huge information regarding ventilator-associated pneumonia 
(VAP) in terms of diagnosis, treatment and impact on the outcome of critically ill 
patients1,2,3. However, nosocomial tracheobronchitis, and specifically Ventilator associated 
Tracheobronchitis (VAT) in the ICU is a definition with a difficult and complicated 
diagnosis4,5,6. VAT represents an entity with several definitions and different treatment 
options up to different authors, without knowing exactly the impact on the outcome of 
critically ill patients. VAT is “microbiologically confirmed” when a patient with clinically 
diagnosed tracheobronchitis yields culture specimens that identify a causative pathogen. 
When a patient lacks fever or leukocytosis (or if culture specimens reveal few organisms) 
the differentiation between colonization and infection is difficult and controversial. 
Furthermore, the significance of tracheobronchial colonization as a risk factor for 
subsequent lower respiratory tract infection remains unclear7. This review attempts to 
summarize the current knowledge on VAT with special interest in the following questions: 
1) What is the most appropriate definition of VAT? 2) How is the diagnosis performed in 
VAT? 3) When a VAT requires antibiotic treatment? and finally 4) What antibiotic treatment 
options might be considered? 
2. Definition  
The incidence of VAT varies widely in the literature8,9,10,11. Malacarne et al7 in a recent 
multicenter study found, in more than 9000 patients included, an incidence of 15.5% 
tracheobronchitis, which is the third most common infection after pneumonia (47%) and 
tract urinary infection (26%). Another study8 showed an incidence of VAT of 10.6%, with a 
prevalence significantly higher in surgical (15.3%) compared to medical patients (9.9%. P = 
0.01). However, the true prevalence of VAT is difficult to compare between studies because 
of the different definitions being used for diagnosis12,13. For the CDC (Centers for Disease 
Control)6 the definition of VAT in adult patients must meet the radiological criteria of 
absence of pneumonia in the X-ray and at least 2 of the following findings: 1) fever (> 38 º C) 
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2) cough, 3) new or increased production of sputum, 4) rhonchi and wheezing and  
5) bronchospasm. In addition, a positive culture of bronchial secretions obtained by 
endotracheal aspirate (ETA) or bronchoscopic technique should be positive.  
Recent studies7,8,14 have used a more updated definition that includes some changes from 
the CDC criteria (Table 1). The VAT is "microbiologically" confirmed if a patient with 
clinical suspicion of VAT has a growth of a potentially pathogenic microorganism with a 
number of colony-forming units (cfu) above the cut-off points for those used in a lower 
respiratory sample4,5,7,11,12,13. However, the definition of VAT has not been validated by 
studies using a comparable diagnosis techniques as a "gold standard." In patients in whom 
some of the items of the definition (fever or leukocytosis) are not present or the number of 
colony-forming units (cfu/ml) are below the suggested cutoff points, the differentiation 
between VAT (infection) and colonization might be difficult.  
 
Criteria frequently used for diagnosis 
 Fever ( Temperature > 38ºC) 
 New or increased sputum production. 
 Leukocytosis. 
 Absence of new pulmonary infiltrates in X-ray. 
Table 1. Criteria for Nosocomial tracheobronchitis. 
Another point to consider in diagnosis refers to the absence of pulmonary infiltrates, 
which remains a controversial issue. In intubated patients admitted to ICU, the clinical 
condition and the technical difficulties in carrying out a portable X-ray make the 
diagnosis of absence of "new thoracic infiltrates", which is required for the diagnosis of 
VAT, difficult to assure and has a marked character of subjectivity. Several 
authors4,5,11,12,13 have also suggested the need to confirm or to rule out the existence of 
new thoracic infiltrates by chest computerized tomography (CT). However, this procedure 
is not always possible or routinely indicated in all ventilated patients when suspected 
VAT and its cost-benefit needs to be clarified. Therefore, it is necessary to assume a broad 
definition for this entity to identify patients at risk for VAT in order to identify those who 
must confirm the diagnosis by using complementary techniques and to decide whether or 
not starting antibiotic treatment. 
3. Immune system interactions 
The upper and lower airways can become colonized independently of each other15, the 
lower respiratory tract becoming colonized as a primary event and does not necessary need 
an initial colonization of the oropharynx, particularly when Gram negative bacilli such as 
Pseudomonas sp are present.   
In mechanically ventilated patients suggest a similar dichotomy between upper and lower 
airway colonization patterns. The upper airways contact with pathogenic microbes, 
therefore immune recognition principles have to be tightly controlled. Nuclear factor (NF)-
kB is an important and highly inducible transcriptional factor activated by a variety of 
microbial components that signal through innate immune toll-like-receptors (TLR) and with 
a pivotal role in the transcription of genes involved in inflammatory response7. Cytokines 
are important mediators in both tracheal defense and inflammation. A constitutive secretion 
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of TGF-β (Transforming Growth Factor) by bronchial and tracheal epithelial showed a direct 
inhibitory effect on T lymphocyte proliferation16.  
Recent studies have demonstrated that bronchial/tracheal epithelial (BEC) cells are 
functionally different and represents a first step of injury17. BEAS-2B bronchial epithelial 
cells are able to inhibit the secretion of the pro-inflammatory cytokines such as TNF-  and 
IL-12 by monocytes, macrophages and dendritic cells.   
Moreover, epithelial cell-conditioned T lymphocytes showed increased differentiation 
towards IL-10-producing Tr1 cells18. Bronchial epithelial cells induce a non-inflammatory 
microenvironment that regulates local immune homeostasis. These include transforming 
growth factor (TGF)- /TGF receptor (TGFR) 1, TNF- /TNFR1, and Fas/Fas ligand (FasL)7  
Human bronchial/tracheal epithelial cells are more sensitive than small airway epithelial 
cells to induced apoptosis apparently due to a Fas response by apoptosis (caspase-8 
activation) stimulation via an amplification loop involving several elements of the caspase  
(-8, -9, -3 and -6 in BEC, but not in SAEC). Again several pathways have been reported to be 
involved in inducing apoptosis of T cells19,7. 
4. Diagnosis  
As mentioned above, there is a lack of agreement for definition but also no consensus on 
how to make a diagnosis of VAT. Several ways of diagnosis have been used and  are mainly 
differentiated on the need for laboratory confirmation and the value assigned to the cutoff 
points of the isolates4,5,6,9,10. 
Typically, the diagnosis of VAT it is considered when a patient under invasive mechanical 
ventilation stars with fever and increased mucus production by endotracheal tube and an 
absence of new radiographic infiltrates, but always after having ruled out other possible foci 
of infection. However, this case scenario is not uncommon in critically ill patients and the 
mere fact of making a diagnosis of VAT may be associated with an unnecessary antibiotic 
treatment resulting in selection pressure on pathogens. Additional information may help to 
accurate the diagnosis of VAT. With the use of a bronchoscopy, the characteristics of 
secretions might be evaluated and also by obtaining a deeper sample is a relatively simple 
procedure that can help in diagnosis13. If during the procedure purulent secretions come 
from the deep portions of the lung, the possibility of VAT diagnosis is increased13.  
Obtaining a sample of respiratory secretions for subsequent quantitative culture is 
mandatory in all patients with suspected VAT. Performing a Gram stain technique in 
respiratory sample allows assessing the degree of inflammation based on the number of 
PML and quickly guiding the antibiotic therapy used. The discovery of a potentially 
pathogenic microorganism in number of 105, 104 or 103 CFU for BAS, BAL and protected 
brush respectively can also help in minimizing antibiotic overtreatment. According to some 
authors4,5,6,11,14,infection can be differentiated from airway colonization and therefore stop 
antibiotic therapy initiated if microbial growth is below the cut-off points mentioned. 
However, due to the complexity of the mechanically ventilated critical patients, it is often 
difficult to distinguish clearly to whom antimicrobial therapy may be discontinued based on 
the cutoff points and a more comprehensive therapeutic approach is needed in order to 
evaluate whether to continue antibiotic treatment.  
Inflammatory biomarkers such as C-reactive protein (CRP) and procalcitonin (PCT) have 
been used for the diagnosis of VAP20,21,22 and may also help in the diagnosis of VAT. Sierra 
et al15 showed that CRP may be a good indicator of infection in patients with inflammatory 
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response syndrome. In addition, while Lisboa et al.16 showed a good correlation between 
bacterial load measured as CFU/ml on quantitative culture of respiratory secretions and 
serum CRP, Povoa et al17 showed that the evolution of serum CRP could be related to the 
recognition and development of VAP. Finally, despite of there is a lack of evidence for VAT 
diagnosis based on CRP, high levels of PCT and CRP (> 30 U / L) probably suggest a high 
bacterial load and a greater inflammatory response secondary more evident when a VAP is 
present.  
Whereas VAP and VAT present similar clinical features, VAT does not involve lung 
parenchyma manifested by thoracic infiltrates in X-ray, therefore to make a differential 
diagnosis remains difficult in critically ill patients. The VAT may represent an intermediate 
process between the colonization of the lower airway and the VAP and should probably be 
interpreted as a continuum and dynamic process between bronchitis and pulmonary 
parenchymal infection5,13. Figure 1. It Therefore, VAT might be considered as "a particular 
clinical entity" that in certain patients may require specific treatment, rather than requiring a 
rigid and uniform definition.  
 
 
Fig. 1. Changes of tracheal colonization on mechanical ventilation patients in accordance to 
endotracheal bronchial aspirate. Note that colonization occurs without clinical signs of 
respiratory infection, Respiratory infection is present when colonization levels (CFU / ml) 
exceed 105. The difference between pneumonia (VAP) and tracheobronchitis (VAT) would 
be determined only by the lack of involvement of lung parenchyma in the VAT (Modified 
from reference 5). 
5. Prevention and treatment  
In an attempt to prevent bacterial colonization several strategies might be taken into 
account. Coated ETTs induced a nonsignificant reduction of the tracheal colonization, 
reduced bacterial colonization of the ETT and ventilator circuits, and prevented lung 
bacterial colonization23.  
In addition the role of tracheostomy in mechanically ventilated patients remains 
controversial. A patient who has a colonized airway and who undergoes percutaneous 
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tracheotomy has an increased risk of VAP in the week following the procedure24,7. The 
presence of a plastic device always causes a low grade of local mucocutaneous 
inflammation. Microorganisms show an affinity for the tracheotomy rather than the 
oropharynx as the site of acquisition. In addition, introduction of microorganisms directly 
into the lower airways via the tracheotomy as a result of repeated suctioning and 
manipulation of the trachea represents an important exogenous pathway. Recently, Nseir et 
al25 reported that tracheotomy was independently associated with a decreased risk of VAP 
due to the fact that liberation of the vocal cords, resulting in a reduced risk of aspiration of 
contaminated oropharyngeal secretions into the lung and the reduction in bacterial biofilm 
formation associated with regular changing of the tracheotomy cannula, but rates of 
tracheobronchitis were not reported. The role of tracheostomy in development of 
tracheobronchitis has not been studied and future research should be performed. 
Prevention of lower respiratory infection in patients under MV is cornerstone in preventing 
the development of VAT. Different prevention strategies may also help to avoid the 
development of VAT and VAP subsequently which must be implemented systematically in 
every patient  (Figure 2).  
 
 
Fig. 2. Ventilator Associated Tracheobronchitis Pathophysiology 
Antibiotic treatment, timing to start antimicrobial and route of administration when a 
patients is affected by a VAT is a subject of ongoing controversy4,5,13.There is little doubt to 
start promptly intravenous antibiotic in a hemodynamically unstable patient under MV 
with fever when VAT is a reasonable diagnosis, and after rolling out other sources of 
infection. However, there are many critically ill patients presenting VAT without 
hemodynamic compromise. In these cases, antimicrobial therapy is questionable. The use of 
antibiotics in VAT has been evaluated in 2 recent Randomized Controlled Trials (RCT). 
Palmer et al26 conducted a double-blind, placebo-control RCT in ICU. Patients were 
assigned to receive antibiotics (ATB) nebulized (gentamicin and / or vancomycin) for 14 
days or until extubation or to receive placebo (saline). Patients assigned to receive nebulized 
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ATB had a lower incidence of VAP, faster weaning and less use of systemic ATB. These 
results should be interpreted with caution, since the administration of systemic ATB was not 
standardized and based on the attending physician. Moreover, quantitative culture of 
respiratory secretions was not performed. In the other hand, Nseir et al14 conducted a 
prospective, multicenter randomized study in intubated patients based on surveillance 
quantitative culture of tracheal aspirates obtained after intubation. Patients were 
randomized to receive or not intravenous ATB for 8 days after performing the diagnosis of 
VAT by a quantitative culture of bronchial secretions with> 106 CFU / ml and a growth of a 
new pathogen not present on admission. The main findings were that the group treated 
with ATB had a lower mortality rate, more VM free-days and lower incidence of VAP. 
While these results are interesting, some important limitations of this study make to 
consider the findings very carefully. The study included only 34 patients after 2 years of 
study but had to be interrupted by the low recruitment and showed lower mortality in the 
interim analysis with a non pre-defined number of patients. In addition, the increased 
mortality in the untreated group might be due to higher incidence of Pseudomonas aeruginosa 
VAP and not directly related to the VAT.  
The results of these prospective studies, although inconclusive, are attractive and open the 
debate regarding when patients affected by VAT should be treated or not with ATB. In our 
opinion, if the patient has clinical signs of VAT with fever, leukocytosis, and purulent 
secretions, a short course of ATB (5-7 days) should be initiated after obtaining a respiratory 
specimen for culture. The administration of aerosolized ATB / nebulized in patients with 
uncomplicated VAT is also a attractive idea, but new well-designed prospective studies are 
warranted in order to implement future therapeutic decisions 
6. Conclusions 
VAT is a relatively common entity in ventilated patients admitted to an ICU. Differential 
diagnosis with VAP is difficult and might require additional information based on 
biomarkers such as CRP or PCT. The development of VAT seems to be associated with an 
increase development of VAP, a longer time under MV, longer hospital stay and possibly 
increased mortality with probably. Recent studies seem to suggest that ATB treatment of 
VAT is associated with lower mortality and a reduction of days of mechanical ventilation. 
Nevertheless and based on the limitations suggested for previous studies conducted, the 
indication to start antibiotic therapy as well as the most effective route of administration 
should be defined by future RCT. 
Until these results are published, the most appropriate behavior in a patient with symptoms 
of VAT seems to correspond to the administration of a short course of systemic ATB.  
7. References 
[1] Vidaur L, Sirgo G, Rodríguez A, Rello J. Clinical approach to the patients with suspected 
ventilador-associated pnuemonia. Respir Care 2005; 50:965-74 
[2] Agbaht K, Lisboa T, Pobo A et al. Management of ventilator-associated pneumonia in a 
multidisciplinary intensive care unit: does trauma make a difference?. Intensive 
Care Med 2007;33:1387-95 
[3] Garnacho-Montero J, Sa-Borges M, Solé-Violán J et al. Optimal management therapy for 
Pseudomonas aeruginosa ventilator-associated pneumonia: An observational, 
www.intechopen.com
 Ventilator Associated Tracheobronchitis 
 
117 
multicenter sutdy comparing monotherapy with combination antibiotic therapy. 
Crit Care 2007; 35:1888-95 
[4] Nseir S, Ader F, Marquette CH. Nosocomial tracheobronchitis. Curr Opin Infect Dis 2009; 
22: 148-153 
[5] Craven DE, Chroneou A, Zias K, Hijalmarson KI. Ventilator-associated tracheobronchitis. 
The impac of target antibiotic therapy on patient outcomes. Chest 2009;135:521-28 
[6] Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial 
infectons, 1988. Am J Infect Control 1988;16:128-40 
[7] Martín-Loeches I, Pobo A. What is new in ventilador-associated tracheobronchitis? Clin 
Pulm Med 2009 (in press) 
[8] Malacarne P. Langer M, Nascimben E et al.  Building a continuous multicenter infections 
surveillance system in the intensive care unit: finding from initial date set of 9493 
patients from 71 Italian intensive care units. Crit Care Med 2008;36;1105-13. 
[9] Nseir S, Di Pompeo C, Pronnier P et al. Nosocomial tracheobronchitis in mechanically 
ventilated patients: incidence aetiology and outcome. Eur Respr J 2002;20:1483-89 
[10] Rouby JJ, De Lassale E, Poete P, et al. Nosocomial bronchopneumonia in the critically 
ill. Histologic and bacteriologic aspects. Am Rev Respir Dis 1992; 146:1059-66 
[11] Rello J, Ausina V, Castella J et al. Nosocomial respiratory tract infections in multiple 
trauma patients : influence of level of consciousness with implications for therapy. 
Chest 1992; 102:525-29. 
[12] Craven DE. Ventilator-associated tracheobronchitis (VAT): questions, answers, and a 
new paradigm?. Crit Care 2008;12:157 
[13] Torres A, Valencia M. Does ventilator-associated tracheobrochitis need antibiotic treat?. 
Crit Care 2005;9:255 
[14] Nseir S, Favory R, Jozefowicz E et al. Antimicrobial treatment for ventilator-associated 
tracheobronchitis: a randomized, controlled, multicenter study. Crit Care 
2008;12:R62. 
[15] Niederman MS, Ferranti RD. Ziegler A, Merrill WW, Reynolds HY. Respiratory 
infection complicating long-term tracheostomy: the implication of persistent gram-
negative tracheobronchial colonization. Chest 1984; 85:39-44 
[16] Ward PA, Lentsch AB Endogenous regulation of the acute inflammatory response. Mol 
Cell Biochem 2002 234–235: 225–228 
[17] Mayer AK, Bartz H, Fey F, Schmidt LM, Dalpke AH Airway epithelial cells modify 
immune responses by inducing an anti-inflammatory microenvironment. Eur J 
Immunol. 2008 Jun;38(6):1689-99. 
[18] Sillett HK, Cruickshank SM, Southgate J, and Trejdosiewicz LK. Transforming growth 
factor-beta promotes `death by neglect' in post-activated human T cells. 
Immunology 2001 102: 310–316. 
[19] R. Ray, B. Keyser, D. Andres, S. Hauck, B. Benton, C. Carpin, A. Daher, C. Simbulan-
Rosenthal, and D. Rosenthal Human bronchial/tracheal epithelial cells (BEC) are 
more sensitive than small airway epithelial cells (SAEC) to sulfur mustard-induced 
apoptosis apparently due to a Fas (death receptor) response amplification loop 
FASEB J. 22: 648.6 
[20] Sierra R, Rello J, Bailén MA et al. C-reactive protein used as an early indicator of 
infection in patients with systemic inflammatory response syndrome. Intensive 
Care Med 2004; 30:2038-45 
www.intechopen.com
  
Bronchitis 
 
118 
[21] Lisboa T, Seligman R, Díaz E et al. C-reactive protein correlatos with bacterial load and 
appropriate antibiotic therapy in suspected ventilator-associated pneumonia. Crit 
Care Med 2008; 36:166-171  
[22] Povoa P, Coelho L, Almeida E et al. C-reactive protein as a marker of ventilador-
associatedpneumonia. Eur Respir J 2005;25:804-12 
[23] Kollef MH, Afessa B, Anzueto A, Veremakis C, Kerr KM, Margolis BD, Craven DE, 
Roberts PR, Arroliga AC, Hubmayr RD, Restrepo MI, Auger WR, Schinner R; 
NASCENT Investigation Group. Silver-coated endotracheal tubes and incidence of 
ventilator-associated pneumonia: the NASCENT randomized trial.JAMA. 2008 Aug 
20;300(7):805-13 
[24] Daniel T, Blandine M, Claude R,etal: Risk and routes for ventilator associated 
pneumonia with Pseudomonas aeruginosa. Am J Respir Crit Care Med 1998; 
157:978-984 
[25] Nseir S, Di Pompeo C, Jozefowicz E, et al. Relationship between tracheotomy and 
ventilator-associated pneumonia: a case–control study. Eur Respir J 2007; 30: 314–
320 
[26] Palmer LB, Smaldone GC, Chen JJ et al. Aerosolized antibiotics and venilator-associated 
tracheobronchitis in the intensive care unit. Crit Care Med 2008;36:2008-13 
www.intechopen.com
Bronchitis
Edited by Dr. Ignacio MartÃn-Loeches
ISBN 978-953-307-889-2
Hard cover, 190 pages
Publisher InTech
Published online 23, August, 2011
Published in print edition August, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Lung parenchyma has been extensively investigated. Nevertheless, the study of bronchial small airways is
much less common. In addition, bronchitis represents, in some occasions, an intermediate process that easily
explains the damage in the lung parenchyma. The main target of this book is to provide a bronchial small
airways original research from different experts in the field.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Ignacio Martin-Loeches, Sara Rosich, Elisabeth Papiol, Pau Castell, Angel Pobo and Alejandro Rodriguez
(2011). Ventilator Associated Tracheobronchitis, Bronchitis, Dr. Ignacio MartÃn-Loeches (Ed.), ISBN: 978-953-
307-889-2, InTech, Available from: http://www.intechopen.com/books/bronchitis/ventilator-associated-
tracheobronchitis
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
